← k3vl4r
Log inGet started →

RXRX (Recursion Pharmaceuticals) Price Forecast

AI-generated price forecast for Recursion Pharmaceuticals (RXRX) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

The desk streams live daily· see the schedule →

As of November 2026: K3vl4r's calibrated AI forecast currently reads RXRX as 1/1 bullish across its horizons (1 of 1 timeframes pointing up), with a last price of 2.51. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP🔬 Deep research

Last price

2.51

AI outlook

1/1 bullish

Timeframes up

1 / 1

Share𝕏PostTelegram

RXRX forecast by horizon

HorizonDirectionCalibrated move (end of horizon)
1-hour——
4-hour——
Daily~4 weeks out▲ Up+40.21%
WeeklyNot enough track record yet—

Calibrated: each horizon's forecast is weighted by how often the model has called RXRX's direction correctly over the last 30 days, and reversed where it has been wrong more often than right. A horizon votes only once it has enough resolved forecasts.

Latest RXRX news

From the market-news feed the forecasts are read against.

  • Recursion Pharmaceuticals Reaches FDA Agreement on Key Endpoint for Phase III FAP Trial · Yahoo · Nov 21
  • Why Recursion Pharmaceuticals Stock Is Up Today · Yahoo · Nov 18
  • Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Lowers Price Target to $5.6 · Benzinga · Nov 18
  • Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis · Yahoo · Nov 18
  • Recursion Has Aligned With the FDA on Its Registrational Phase 3 Trial of Rec-4881 for Familial Adenomatous Polyposis; Trial on Track to Begin in 2H of 2027 · Benzinga · Nov 18

🔒

See the full RXRX forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

RXRX forecast — frequently asked

Will RXRX go up?

K3vl4r's calibrated AI forecast currently reads RXRX as 1/1 bullish — 1 of 1 forecast horizons point up, so the overall read is leaning to the upside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the RXRX price prediction for 2026?

K3vl4r's model projects RXRX toward $3.44 over the next ~4 weeks, a +40.2% move from $2.45. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Biotech & Pharma forecasts — browse the full sector.

More AI forecasts

IRWDTMDXAMGNSRPTBIIBNVAXINCYFATEGILDBCRXUTHRCDNAPRTANTLA

Will RXRX reach…?

Will RXRX reach $3.00?Will RXRX reach $5.00?Will RXRX reach $10.00?Will RXRX reach $20.00?

Or see the full RXRX price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare RXRX

RXRX vs IRWDRXRX vs TMDXRXRX vs AMGNRXRX vs SRPTRXRX vs BIIBRXRX vs NVAX

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

StreamWatch on Kick·Watch on YouTube
k3vl4rResearch libraryTrack recordChart indicatorsToday's outlookStream scheduleBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch the desk stream live on Kick or YouTube. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.